Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: A retrospective analysis in bisphosphonate-treated patients

Clinical Cancer Research

Volumn 18, Issue 22, 2012, Pages 6348-6355

  Brown, Janet E ^a,b   Cook, Richard J ^c   Lipton, Allan ^d   Coleman, Robert E ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b WESTON PARK HOSPITAL   (United Kingdom)

^c UNIVERSITY OF WATERLOO   (Canada)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; PAMIDRONIC ACID; TUMOR MARKER; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT;

AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84869209128     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1397     Document Type: Article

References (46)

1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76. (Pubitemid 32452017)
2. Kinnane N. Burden of bone disease. Eur J Oncol Nurs 2007;11 suppl 2:S28-31.
3. Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid orpamidronate disodium for metastatic bone lesions. Med Care 2004;42:164-75.
4. Sutherland CM, Mather FJ. Charity Hospital experience with long-term survival and prognostic factors in patients with breast cancer with localized or regional disease. Ann Surg 1988;207:569-80.
5. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010;28:92-8.
6. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-9. (Pubitemid 44200649)
7. U.S. Food and Drug Administration. CellSearch™ Epithelial Cell Kit/CellSpotter™ Analyser - K031588 [cited 2012 16 April]. Available from: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm081239.htm. 2009.
8. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-9.
9. Diamond JR, Finlayson CA, Borges VF. Hepatic complications of breast cancer. Lancet Oncol 2009;10:615-21.
10. Tampellini M, Berruti A, Gerbino A, Buniva T, Torta M, Gorzegno G, et al. Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 1997;75:698-702. (Pubitemid 27091084)
11. Dunphy FR, Spitzer G, Fornoff JE, Yau JC, Huan SD, Dicke KA, et al. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 1994;73:2157-67. (Pubitemid 24107971)
12. Kuru B, Camlibel M, Dinc S, Gulcelik MA, Gonullu D, Alagol H. Prognostic factors for survival in breast cancer patients who developed distant metastasis subsequent to defi nitive surgery. Singapore Med J 2008;49:904-11.
13. Yavas O, Hayran M, Ozisik Y. Factors affecting survival in breast cancer patients following bone metastasis. Tumori 2007;93:580-6. (Pubitemid 351158069)
14. Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998;77:336-40. (Pubitemid 28029553)
15. Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003;89:2031-7. (Pubitemid 38030899)
16. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69.
17. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008;113:193-201. (Pubitemid 351976401)
18. Lipton A, Demers L, Curley E, Chinchilli V, Gaydos L, Hortobagyi G, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998;34:2021-6. (Pubitemid 28546935)
19. Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE. Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer. 2009;9:272.
20. Kaminski M, Rosen LS, Gordon D, Zheng M, Hei Y-J. Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications [poster]. Presented at: Primary Therapy of Early Breast Cancer 9th International Conference; 2005 Jan 26-29; St. Gallen, Switzerland. Abstract 107.
21. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87. (Pubitemid 33759002)
22. Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36-43. (Pubitemid 37553537)
23. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44. (Pubitemid 37238631)
24. Brown JE,Cook RJ, Lipton A,Costa L, Coleman RE. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat 2010;123:767-79.
25. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-26.
26. Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic signi ficance. Leuk Lymphoma 2007;48:337-41. (Pubitemid 46994883)
27. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558-65.
28. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002;20:3972-82.
29. Tas F, Aydiner A, Demir C, Topuz E. Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am J Clin Oncol 2001;24:376-8. (Pubitemid 32730733)
30. Coleman RE, Brown JE, Cook R. Serum lactate dehydrogenase (LDH) is a significant prognostic variable for survival in patients with metastatic breast cancer: a multivariate analysis [poster]. Presented at: EBCC 6: European Breast Cancer Conference; 2008 Apr 15-19; Berlin, Germany. Abstract nr 468.
31. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6. (Pubitemid 17234155)
32. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-35. (Pubitemid 46223998)
33. Bacci G, Ferrari S, Longhi A, Rimondini S, Versari M, Zanone A, et al. Prognostic significance of serum LDH in Ewing's sarcoma of bone. Oncol Rep 1999;6:807-11.
34. Stokkel MP, van Eck-Smit BL, Zwinderman AH, Willems LN, Pauwels EK. Pretreatment serum lactate dehydrogenase as additional staging parameter in patients with small-cell lung carcinoma. J Cancer Res Clin Oncol 1998;124:215-9. (Pubitemid 28216234)
35. Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 1987;39:146-9. (Pubitemid 17015271)
36. Eigentler TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 2011;117:1697-703.
37. Egberts F, Kotthoff EM, Gerdes S, Egberts JH, Weichenthal M, Hauschild A. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. Eur J Cancer 2012;48:695-702.
38. Chibaudel B, Bonnetain F, Shi Q, Buyse M, Tournigand C, Sargent DJ, et al. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy - an Aide et Recherche en Cancerologie Digestive Group Study. J Clin Oncol 2011;29:4199-204.
39. Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E, Delimpasi S, et al. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. Eur J Haematol 2010;85:114-9.
40. Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, et al. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 1998;16:2401-8. (Pubitemid 28309034)
41. Le Scodan R, Massard C, Jouanneau L, Coussy F, Gutierrez M, Kirova Y, et al. Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment. J Neurooncol 2012;106:169-76.
42. Tredan O, Ray-Coquard I, Chvetzoff G, Rebattu P, Bajard A, Chabaud S, et al. Validation of prognostic scores for survival in cancer patients beyond first-line therapy. BMC Cancer 2011;11:95.
43. Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006;12:3361-7.
44. Naruse K, Yamada Y, Aoki S, Taki T, Nakamura K, Tobiume M, et al. Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis. Hinyokika Kiyo 2007;53:287-92.
45. Yamada Y, Nakamura K, Aoki S, Tobiume M, Zennami K, Kato Y, et al. Lactate dehydrogenase, Gleason score and HER-2 overexpression are significant prognostic factors for M1b prostate cancer. Oncol Rep 2011;25:937-44.
46. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009;10:233-9.